We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current TVTX market cap is 476.38M. The company's latest EPS is USD -1.4639 and P/E is -4.28.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 53.5M | 55.87M | 56.99M | 59.7M | -16.51M |
| Operating Income | -68.13M | -66.85M | -87.05M | -87.58M | -127.87M |
| Net Income | -69.66M | -65.82M | -86.33M | -85.63M | 150.74M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 193.34M | 198.32M | 227.49M | 212.02M | 145.24M |
| Operating Income | -122.36M | -176.16M | -161.77M | -266.57M | -388.14M |
| Net Income | -146.43M | -169.43M | -180.09M | -278.48M | -111.4M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 726.22M | 672.59M | 808.23M | 736.43M | 832.85M |
| Total Liabilities | 625.54M | 629.73M | 619.09M | 619.94M | 553.08M |
| Total Equity | 100.68M | 42.85M | 189.14M | 116.49M | 279.77M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 604.8M | 607.44M | 776.63M | 672.59M | 788.91M |
| Total Liabilities | 383.6M | 396.23M | 474.52M | 629.73M | 588.1M |
| Total Equity | 221.2M | 211.21M | 302.11M | 42.85M | 200.81M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -131.65M | -186.29M | -81.12M | -150.41M | -209.55M |
| Investing | 4.15M | -32.55M | -37.04M | -60.59M | 72.73M |
| Financing | 117.02M | 117.57M | 217M | 219.26M | 218.63M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -58.21M | -42.74M | -14.79M | -186.29M | -280.02M |
| Investing | 19.86M | -61.33M | -137.62M | -32.55M | 55.78M |
| Financing | -2.08M | 127.71M | 231.68M | 117.57M | 218.75M |
| Market Cap | 476.38M |
| Price to Earnings Ratio | -4.28 |
| Price to Sales Ratio | 3.28 |
| Price to Cash Ratio | 8.19 |
| Price to Book Ratio | 2.37 |
| Dividend Yield | - |
| Shares Outstanding | 76.1M |
| Average Volume (1 week) | 1.46M |
| Average Volume (1 Month) | 1.44M |
| 52 Week Change | -59.38% |
| 52 Week High | 19.5424 |
| 52 Week Low | 5.12 |
| Spread (Intraday) | 0.57 (8.73%) |
| Company Name | Travere Therapeutics Inc |
| Address |
16192 coastal hwy lewes, delaware 19958 |
| Website | https://travere.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
